In PM360 Magazine, Saama Founder and CEO, Suresh Katta, along with Chief Life Sciences Officer Kenneth L. Massey, explain how AI-powered analytics can help sponsors and regulators strike the right balance between risk and reward.
“Common perception is that [the FDA] is solely risk-averse,” write the authors. “However, regulators have also demonstrated a notable inclination for embracing risk when it is clearly in the public’s best interests.”
Noting the FDA’s openness to innovation, the article makes a compelling case for the power of disruptive technology—specifically AI-informed analytics platforms—to reduce inherent risks along the drug development, review, and approval continuum.
Access Out-of-the-Box Features in 4 Weeks—Guaranteed.
Saama can put you on the fast track to clinical trial process innovation.